series-a
Stage
2020
Founded
1
Investors
About
ActiTrexx develops activated regulatory T cells (ATreg) to prevent rejection reactions in patients undergoing stem cell transplants and to treat autoimmune diseases by rebalancing dysregulated immune systems.
Explore ActiTrexx GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.